Log in
Enquire now
‌

Autoimmune and Autoinflammatory Genetics Study

OverviewStructured DataIssuesContributors

Contents

clinicaltrials.gov/study/NCT06004349
Is a
‌
Clinical study
0

Clinical Study attributes

NCT Number
NCT060043490
Health Conditions in Trial
Autoimmune disease
Autoimmune disease
0
Trial Recruitment Size
1,5000
Clinical Trial Start Date
April 15, 2022
0
Primary Completion Date
April 5, 2032
0
Study Completion Date
April 5, 2032
0
Clinical Trial Study Type
Observational0
Observational Clinical Trial Type
Cohort0
Observational Study Perspective
Prospective0
Official Name
Natural History and Genetics of VEXAS Syndrome and Related Autoinflammatory Syndromes0
Last Updated
October 2, 2023
0
Study summary

This is an exploratory natural history protocol that will enroll patients with known genetic diseases, such as VEXAS syndrome, or as yet undiagnosed disorders of inflammation with the goal of improving our understanding of disease processes. Blood, saliva, hair, nail, or buccal samples may be collected for genetic analysis, blood samples will be obtained for immunologic and other functional studies, and a small number of subjects may undergo skin biopsy.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like Autoimmune and Autoinflammatory Genetics Study

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Pricing
  • Become an Editor
  • Enterprise

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us

Explore companies

  • Artificial Intelligence
  • Fintech
  • Biotechnology
  • Cybersecurity
  • Semiconductors
  • Electric Vehicles
  • Cloud Computing
  • Robotics
  • SaaS
  • Renewable Energy
  • Venture Capital
  • Blockchain
  • Browse all →
By using this site, you agree to our Terms of Service.